Cell and Gene Therapy

Bispecifics

Bispecific T-cell engagers (BiTEs) are an emerging class of therapeutic antibodies designed to simultaneously target proteins on both tumor cells and immune cells, opening new avenues for personalized and effective medical interventions. This innovative approach may lead to improved efficacy and reduced side effects compared to other available treatments.

Northwest Medical Specialties is proud to offer a comprehensive bispecific immunotherapy program as part of its ongoing efforts to enhance treatment options and improve outcomes. Patients who are eligible for these treatments are provided with increased support and monitoring as part of the program.

Several BiTE therapies have been approved by the FDA, and more are on the way. NWMS is also participating in multiple clinical trials using these treatments in the outpatient setting. These studies allow our providers to investigate how BiTEs could benefit additional groups of patients. Patients who participate in clinical trials contribute critical data to the future of cancer treatment. NWMS is proud to provide this opportunity to eligible patients.

Trispecifics

Trispecifics are similar to bispecifics in that they function as T-cell engagers, but they are designed to bind three distinct targets at once. Trispecific antibodies typically target an immune cell and two different tumor antigens. This multi-target approach helps direct and amplify the body’s immune response against cancer. Trispecifics are being developed with the goal of improving efficacy over bispecifics by increasing tumor specificity.

Patients and referring physicians are encouraged to reach out to Northwest Medical Specialties for more information about our bispecific (BiTE therapy) and trispecific programs, and to discuss potential treatment options. Patients who are eligible for these treatments are provided with increased support and monitoring as part of the program.